RespireRx Pharmaceuticals Inc

RespireRx Pharmaceuticals — Biotech Showcase 2016

34 slides from RespireRx Pharmaceuticals's conference presentation, Jan 11, 2016

  1. Slide 1: Medicines for Respiratory Diseases

    Pharmaceuticals Inc James S. Manuso, Ph.D., President and CEO January 11, 2016 BIoTECH SHOWCASE 2016 Medicines for Respiratory Diseases 1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements CQ RespireRx Pharmaceuticals Inc The matters discussed in this presentation that are not historical facts are "forward-looking statements." Forward-looking statements include, but are not limited to, statements containing the words "believes," "anticipates," "intends," "ex

  3. Slide 3: Breath quote

    Breath GR) RespireRx "Breath is the universal factor of life. We are born the first time we inspire, and we die the last time we expire. Breath is life itself. In Sanskrit the same word means both breath and life." —— Abbot George Burke

  4. Slide 4: The RespireRx Story: Innovative Medicines for Respiratory Diseases

    The RespireRx Story: Innovative Medicines for Respiratory Diseases d)Resp pireRx Pharmaceuticals Inc o Two drug platforms o Three Phase 2 or Phase 2-ready programs o One pre-clinical program o Blockbuster markets o IP protection with the ability to add additional IP o Multiple opportunities for stra

  5. Slide 5: Company Focus

    Company Focus Gd RespireRx o Sleep Apneas = Dronabinol for Obstructive Sleep Apnea (OSA) = Ampakines for Central Sleep Apnea (CSA) o Drug-induced Respiratory Depression (RD) - Ampakines = Semi-acute use — post-surgical pain management with opioids = Acute use — surgical anesthesia/sedation = Chronic

  6. Slide 6: Respiratory Diseases Product Pipeline

    Respiratory Diseases Product Pipeline dQ Resp pireRx Pharmaceuticals Inc Compound Indication Pre-clinical Dronabinol Obstructive Sleep Apnea Central Sleep Apnea CX1739 Opioid-induced RD Spinal Damage/Pompe Combination Formulation with Opioids for Reduced RD Cx1942 Drug-induced Respiratory Depression

  7. Slide 7: Sleep Apnea

    Sleep Apnea AdRespireRx o Sleep Apnea = Repetitive episodes of airflow cessation (apnea) or reduction (hypopnea) for more than 10 seconds during sleep = Three types: Obstructive, Central & Mixed o The Sleep Apnea Market is Large = 18 million U.S. adults suffer from moderate or severe sleep apneas =

  8. Slide 8: Obstructive Sleep Apnea (OSA)

    Obstructive Sleep Apnea (OSA) Ad RespireRx o Obstructive Sleep Apnea (OSA): a decrease or complete halt in airflow during sleep = Induced by relaxation of muscles during sleep = Soft tissue in back of throat collapses and obstructs upper airway o Significant morbidity due to stroke, hypertension, he

  9. Slide 9: CPAP Efficacy is Severely Limited by Patient Compliance

    CPAP Efficacy is Severly Limited by Patient Compliance WN RespireRx o Works as an air splint to keep upper airway open during sleep o 30% of diagnosed patients never initiate CPAP treatment when prescribed a machine o Over 50% of patients stop using CPAP in the first year o Many CPAP users wear the

  10. Slide 10: Dronabinol: a Breakthrough Treatment for OSA

    Dronabinol: a BreakthroughTreatment for OSA RespireRx Pharmaceuticals Inc o Mechanism of Action = Dronabinol is (D-9)THC, a cannabinoid agonist o Background " Schedule III drug available by prescription, with a low risk of addiction = Approved for the treatment of anorexia in AIDS patients and nause

  11. Slide 11: Completed Phase 2A Trial of Dronabinol in OSA

    Completed Phase 2A Trial of Dronabinol in OSA Resp ireRx o Randomized, double-blind, placebo-controlled dose escalation study in 22 patients with OSA o Placebo (N=5) or dronabinol (N=17) for 21 days = 2.5, 5 and 10 mg/night studied with weekly dose escalation o Overnight polysomnogram (PSG) at basel

  12. Slide 12: Dronabinol Proven to Reduce Apnea in OSA Subjects

    Dronabinol Proven to Reduce Apnea in OSA Subjects >\ RespireRx Pharmaceuticals Inc P=0.17 Dronabinol Placebo P<0.01 Reduction in Sleep Apnea 3 2

  13. Slide 13: Apnea Suppression as a Function of Dose Time

    Apnea Suppression as a Function of Dose Time Resp pireRx Pharmaceuticals Inc = 1st Half = 2nd Half AAHI versus Baseline n=17 n=13 n=8 The plasma half-life of dronabinol is 2 — 4 hours. 13

  14. Slide 14: Ongoing Dronabinol Phase 2B Clinical Trial in OSA

    Ongoing Dronabinol Phase 2B Clinical Trial in OSA CA RespireRx o Sponsored and led by U of Illinois o 4 major centers, fully funded by NIH © Potentially pivotal for an accelerated NDA o 120 subjects (40/group, 6 wks dosing) o Doses: Placebo, 2.5 mg, 10 mg qd o Data expected Q3/2016 o Plan to meet wi

  15. Slide 15: Protecting Dronabinol in the Market

    Protecting Dronabinol in the Market Ad RespireRx o License to issued Method-of-Use patent for dronabinol in OSA = Expires in 2025 o Schedule Ill drug: off-label use monitored by US government, discouraging generic manufacturers from selling off-label o Off-label use of generics and medical marijuana

  16. Slide 16: The Dronabinol Opportunity

    The Dronabinol Opportunity (A RespireRx Pharmaceuticals Inc Impact on Patient Commercial Opportunity First pharmacotherapeutic available for OSA Ease of Use/Better Patient Compliance Low cost Safe and effective Potential for better cardiovascular outcomes Changes the nature of OSA treatment Broadly

  17. Slide 17: Central Sleep Apnea

    Central Sleep Apnea o Caused by a lack of drive from the brain to breathe during sleep o Manifestations of CSA = 70% of chronic narcotic users = Up to 40% of heart failure patients = 5% of sleep apnea patients are idiopathic o No therapeutic or device is approved for the indication 17 RespireRx Phar

  18. Slide 18: Severity of CSA is Correlated with Increased Mortality in HF Patients

    The Severity of CSA is Correlated with Increased Mortality in HF Patients dQ RespireRx Pharmaceuticals Inc we 9: a ei " 6 AHI less than 5 per hour a we AHI equal or greater than S per hour xo . Ba 3 _ Reducing Central z.. i g Sleep Apnea May @ y a Reduce Mortality in 2 — l Heart Failure Patients ee

  19. Slide 19: Ampakines - A Novel Class of Drugs

    RespireRx eed adie Inc AMPAKINES — A NOVEL CLASS OF DRUGS WB AMPA Receptors Mediate Synaptic Transmission in the Brain AMPAKINE o Glutamate is the major excitatory neurotransmitter in ——— the CNS o Fast excitatory transmission is mediated by AMPA-type glutamate receptors ~~ Presynaptic N o Ampakines

  20. Slide 20: Ampakines - Novel Treatment for Respiratory Depression

    AMPAKINES - Novel Treatment for Respiratory Depression . WN RespireRx Pharmaceuticals Inc PreBotzinger ~S& PreBétzinger Complex Complex Neurons in this brainstem region control inspiratory ‘ breathing rhythm B- intercostal co fo} PreBotC neurons use AMPA receptors for signaling fo} o Opioids and oth

  21. Slide 21: CX1739: A Third Generation, Oral Ampakine in Phase 2

    CX1739: A Third Generation, Oral Ampakine in Phase 2 GO RespireRx Pharmaceuticals Inc o Targeted Indications = Central Sleep Apnea (CSA) = Reversal and prevention of opioid-induced Respiratory Depression (RD) = Combination formulation with an opioid for treatment of chronic pain o Stage of Developme

  22. Slide 22: CX1739: IND Status

    CX1739: IND Status GO RespireRx Pharmaceuticals Inc o IND = Opioid induced respiratory depression study = Submitted to FDA on September 18, 2015 o FDA noted two deficiencies = Myocardial Histology v FDA requested tissue analysis for all rats at all doses v Analysis completed v No drug-related histop

  23. Slide 23: CX1739: Completed Phase 2A in Sleep Apnea

    CX1739: Completed Phase 2A in Sleep Apnea ip 4 RespireRx chi ane et Inc Design Randomized, double-blind, placebo-controlled study Population 20 adults with all types of moderate to severe sleep apnea (16 given CX1739; 4 given Placebo) Dosing Each subject received either placebo ora single dose of 90

  24. Slide 24: Patient Selection: CX1739 Was More Effective in Mixed and Central Sleep Apneas

    Patient Selection: CX1739 Was More Effective in Treating Mixed and Central Sleep Apneas oS RespireRx Obstructive Apneas Mixed Apneas Central Apnea 35 6 12 30 5 10. xem xm xn STB oo4 ST 4 DE DE BE £3 20 £3 £G oe wo £3 we 6 29% 2: 23 ow a 2 am 4 au et eu ; : a ; 0 0 0 = r r 7 r r + + + r + ~ ara Ye ye

  25. Slide 25: Drug-induced Respiratory Depression

    Drug-induced Respiratory Depression CA) RespireRx RD is the most frequent lethal side effect of opioid use o Acute and Semi-Acute Use of opioids = ~25M patients/year at risk for RD (hospitalized, peri- and post-surgical opioid patients) o Chronic Opioid Use = Use of Ampakines in combination with oth

  26. Slide 26: Two clinical studies with CX717 in healthy volunteers

    » Two clinical studies in normal, healthy volunteers with CX717, a second-generation Ampakine > Moderate Respiratory Depression was induced experimentally by infusion of the opioid, Alfentanil © Respiratory and analgesia end-points were measured 26 Pharmaceuticals Inc

  27. Slide 27: Breaths/min

    Breaths/min = a = NS © S Baseline +e +Alfentanil NS +Naloxone C—Placebo Gagcx717 *P<0.01 NS - Not Significant 27

  28. Slide 28: Analgesia: pain sensitivity with CX717

    Vv ] Delivery of a electrical stimulation to finger Analgesia Pain Sensitivity 2.0: ~ a a S S a 0.0: Pharmaceuticals Inc Analgesia [Placebo CX717 NS Baseline +Alfentanil +Naloxone Data are expressed as the pain sensitivity, normalized to the Baseline measurement N = 15 and 16 per group. CX717 dose i

  29. Slide 29: Respiratory Diseases Product Pipeline

    Respiratory Diseases Product Pipeline dQ Resp pireRx Pharmaceuticals Inc Compound Indication Pre-clinical Dronabinol Obstructive Sleep Apnea Central Sleep Apnea CX1739 Opioid-induced RD Spinal Damage/Pompe Combination Formulation with Opioids for Reduced RD Cx1942 Drug-induced Respiratory Depression

  30. Slide 30: Key Objectives for 2016 (Pending Financing)

    Compound Dronabinol CX1739 CX1739 / CX717 CX717 CX1942 Key Objectives for 2016 (Pending Financing) Indication Obstructive Sleep Apnea Opioid-induced RD Central Sleep Apnea Spinal Cord Injury, Pompe Disease, other Combination formulation with opioid Injectable for RD Status Phase 2B Phase 2A Phase 2A

  31. Slide 31: Capital Structure & Market Metrics

    Capital Structure (in thousands of shares) & Market P Metrics Oxiemmirers Total As of September 30, 2015 Common Stock 477,221 Common Stock Equivalents of all Convertibles (Preferred Stock and Convertible Notes) 95,934 Common Stock Equivalents of all Options and 380,247 Warrants Total 953,402 Po isss

  32. Slide 32: Management and Directors

    RespireRx eed adie Inc Manageme d Directors aN James Manuso President, CEO & Vice Chairman Arnold Lippa CSO & Chairman Jeff Margolis VP, Secretary/Treasurer, Director Robert Weingarten CFO, Director Richard Purcell Senior VP, R&D Katie MacFarlane Director CCO Agile Therapeutics James Sapirstein Dire

  33. Slide 33: The RespireRx Story: Innovative Medicines for Respiratory Diseases

    The RespireRx Story: Innovative Medicines for Respiratory Diseases CX) ResplreRx o Two drug platforms o Three Phase 2 or Phase 2-ready programs o One pre-clinical program o Blockbuster markets o IP protection with the ability to add additional IP o Multiple opportunities for strategic collaborations

  34. Slide 34: Medicines for Respiratory Diseases

    Pharmaceuticals Inc James S. Manuso, Ph.D., President and CEO January 11, 2016 BIoTECH SHOWCASE 2016 Medicines for Respiratory Diseases 34

RespireRx Pharmaceuticals — Biotech Showcase 2016 on 6ix